BGMS — Bio Green Med Solution Share News
0.000.00%
Last trade - 00:00- $5.02m
- $1.68m
- $0.75m
Cyclacel Pharmaceuticals Inc expected to post a loss of 66 cents a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of 66 cents a share - Earnings Preview
Brief: Cyclacel Pharmaceuticals Inc Does Not Hold Any Deposits At Svb
Brief: Cyclacel Pharmaceuticals Reports Q4 And FY 2022 Financial Results And Provides Business Update
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Cyclacel Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Cyclacel Pharmaceuticals - Received Nasdaq Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard Transfer Of Listing On Jan 4
Brief: Cyclacel Pharmaceuticals Reviews 2022 Achievements
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results
Cyclacel Pharmaceuticals Inc expected to post a loss of 56 cents a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of 56 cents a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of 56 cents a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of 56 cents a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of 56 cents a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial Of Oral Fadraciclib
Brief: Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34Th Eortc-Nci-Aacr Symposium
U.S. STOCKS ON THE MOVE-Warby Parker, NV5 Global, Absci